Anixa Biosciences up on U.S. patent for ovarian cancer vaccine technology

Anixa Biosciences

18/08/2021 14:23

** Biotech co's  ANIX.O  shares rise ~8% to $4.37 premarket
    ** U.S. Patent and Trademark Office issues first U.S. patent
for co's ovarian cancer vaccine technology  urn:newsml:reuters.com:*:nPn6t8SF0a
    ** Vaccine candidate targets AMHR2-ED protein, that is
normally expressed only in ovaries of pre-menopausal women, and
trains immune system to destroy ovarian cancer cells as they
arise - ANIX
    ** Anixa is the worldwide licensee of the technology which
was invented and developed at Cleveland Clinic
    ** Stock up ~32% this year, as of last close

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))